Literature DB >> 21041405

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Charles J David1, James L Manley.   

Abstract

Alternative splicing of mRNA precursors is a nearly ubiquitous and extremely flexible point of gene control in humans. It provides cells with the opportunity to create protein isoforms of differing, even opposing, functions from a single gene. Cancer cells often take advantage of this flexibility to produce proteins that promote growth and survival. Many of the isoforms produced in this manner are developmentally regulated and are preferentially re-expressed in tumors. Emerging insights into this process indicate that pathways that are frequently deregulated in cancer often play important roles in promoting aberrant splicing, which in turn contributes to all aspects of tumor biology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041405      PMCID: PMC2964746          DOI: 10.1101/gad.1973010

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  242 in total

1.  Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase.

Authors:  Dennis Fiegen; Lars-Christian Haeusler; Lars Blumenstein; Ulrike Herbrand; Radovan Dvorsky; Ingrid R Vetter; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2003-11-18       Impact factor: 5.157

2.  The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20.

Authors:  Delphine Galiana-Arnoux; Fabrice Lejeune; Marie-Claude Gesnel; James Stevenin; Richard Breathnach; Fabienne Del Gatto-Konczak
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

3.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

4.  SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5' splice site selection of Bcl-x pre-mRNA.

Authors:  Autumn Massiello; James R Roesser; Charles E Chalfant
Journal:  FASEB J       Date:  2006-06-21       Impact factor: 5.191

Review 5.  The superfamily of arginine/serine-rich splicing factors.

Authors:  X D Fu
Journal:  RNA       Date:  1995-09       Impact factor: 4.942

6.  Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter.

Authors:  G Biamonti; M T Bassi; L Cartegni; F Mechta; M Buvoli; F Cobianchi; S Riva
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

7.  Polypyrimidine tract-binding protein enhances the internal ribosomal entry site-dependent translation of p27Kip1 mRNA and modulates transition from G1 to S phase.

Authors:  Sungchan Cho; Jong Heon Kim; Sung Hoon Back; Sung Key Jang
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

8.  TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha.

Authors:  M Piecyk; S Wax; A R Beck; N Kedersha; M Gupta; B Maritim; S Chen; C Gueydan; V Kruys; M Streuli; P Anderson
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

9.  Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  Hum Mol Genet       Date:  2009-07-13       Impact factor: 6.150

10.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

View more
  410 in total

1.  Modulation of RNA splicing as a potential treatment for cancer.

Authors:  John A Bauman; Ryszard Kole
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

Authors:  Davide Rossi; Alessio Bruscaggin; Valeria Spina; Silvia Rasi; Hossein Khiabanian; Monica Messina; Marco Fangazio; Tiziana Vaisitti; Sara Monti; Sabina Chiaretti; Anna Guarini; Ilaria Del Giudice; Michaela Cerri; Stefania Cresta; Clara Deambrogi; Ernesto Gargiulo; Valter Gattei; Francesco Forconi; Francesco Bertoni; Silvia Deaglio; Raul Rabadan; Laura Pasqualucci; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

Review 3.  Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials.

Authors:  Catherine D Mao; Stephen W Byers
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

4.  ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2012-01       Impact factor: 9.941

5.  Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins.

Authors:  Mo Chen; Charles J David; James L Manley
Journal:  Nat Struct Mol Biol       Date:  2012-02-05       Impact factor: 15.369

6.  Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Authors:  Bin Wang; U-Ging Lo; Kaijie Wu; Payal Kapur; Xiangyang Liu; Jun Huang; Wei Chen; Elizabeth Hernandez; John Santoyo; Shi-Hong Ma; Rey-Chen Pong; Dalin He; Yi-Qiang Cheng; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2017-07-31       Impact factor: 7.396

7.  Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells.

Authors:  Huan-Huan Wei; Yuanlong Liu; Yang Wang; Qianyun Lu; Xuerong Yang; Jiefu Li; Zefeng Wang
Journal:  J Vis Exp       Date:  2017-04-26       Impact factor: 1.355

8.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

9.  MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.

Authors:  L Liu; C Luo; Y Luo; L Chen; Y Liu; Y Wang; J Han; Y Zhang; N Wei; Z Xie; W Wu; G Wu; Y Feng
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

Review 10.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.